





Pharming Group NV

Sijmen de Vries Chief Executive Officer

> Investor Tour Zwolle

4th October 2018

Safe Harbour Statement



The information contained in this document and communicated verbally to you (together the "Presentation") is being supplied to you solely for your information and may not be copied, reproduced or further distributed to any person or published, in whole or in part, for any purpose.

The Presentation does not form any part of an offer of, or invitation to apply for, securities in Pharming Group N.V. (the "Company").

The Presentation speaks as of the date shown on the front cover. The Company assumes no obligation to notify or inform the recipient of any developments or changes occurring after the date of this document that might render the contents of the Presentation untrue or inaccurate in whole or in part. In addition, no representation or warranty, express or implied, is given as to the accuracy of the information or opinions contained in the Presentation and no liability is accepted for any use of any such information or opinions given by the Company or by any of its directors, members, officers, employees, agents or advisers.

The Presentation contains forward-looking statements, including statements about our beliefs and expectations. These statements are based on our current plans, estimates and projections, as well as our expectations of external conditions and events. Forward-looking statements involve inherent risks and uncertainties and speak only as of the date they are made. The Company undertakes no duty to update these and will not necessarily update any of them in light of new information or future events, except to the extent required by applicable law.

The Company's securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration under the Securities Act or an available exemption from, or transaction not subject to, the registration requirements of the Securities Act.

Agenda



19:00 uur - Receptie
19:25 uur - Welkomstwoord
19:30 uur - Korte corporate presentatie
20:00 uur - Sijmen de Vries Q&A met Leon Melens
20:30 uur - Audience Q&A
21:00 uur - Aanvang borrel
22:00 uur - Einde

Company Overview

Pharming

- Euronext: PHARM: ~€585 million (~\$678 million) at €0.95 per share
- Headquarters in NL, R&D in France, EU and US: 170 employees in total
- 1st product approved and marketed : RUCONEST®
 - Recombinant human C1-esterase inhibitor (enzyme replacement therapy)
 - For acute angioedema attacks in patients with hereditary angioedema (HAE)
 - Marketed in USA, EU, Korea and Israel with other territories coming
 - Now being explored for larger indications: pre-eclampsia, CIN, Cardiac Protection, DGF
- Platform technology makes recombinant human molecules cleanly and efficiently
- New Enzyme Replacement Therapies (ERT) for other genetic conditions about to enter clinic



Three horizons of growth





- Low volume IV
- Subcutaneous
- Intramuscular
- Painless intradermal
- Prophylaxis for HAE



Meeting other unmet medical needs with the same product

- Pre-eclampsia
- Others such as Contrast-induced Nephropathy, Cardiac Protection, Delayed Graft Function and Hypovolemic Shock

Meeting other unmet medical needs with another products

- α-glucosidase (Pompe)
- α-galactosidase (Fabry)
- Others




Add more RUCONEST[®] sales

Add more products to sell

US Market for HAE drugs




~\$1.7 billion Sales in 2017 (Year-on-year growth 17%)



US quarterly sales development in volumes





What patients want when living with HAE





Patients want a therapy that is convenient and pain-free



"My veins are shot, so I inject my medicine in my stomach. It is so painful and my stomach has bruises everywhere. I wish I had a medicine that didn't hurt and was quick and easy to use."

Formulation development of RUCONEST®



- The "RUCONEST[®] liquid" formulation (14ml \rightarrow 3ml) can be used as starting material for the generation of subcutaneous, intra-muscular & intradermal application systems
- New proprietary 'painless' intradermal delivery applications are being developed:
- Dissolving point device: mmmm • Reservoir device: Ó mmm www
- These painless versions should differentiate RUCONEST[®] from competitors, all of whom have painful injections



Initial Therapeutic Indications selected:

New Potential Indications using existing formulation


- Organ damage after contrast media application:- Contrast-induced Nephropathy (CIN) (ongoing Investigator initiated study)
- Tissue Damage after Toxic Event :- Pre-Eclampsia (Zwangerschapsvergiftiging) (new Pharming)
- Tissue Damage after Hypoxic Event :- Delayed Graft Function (new Investigator initiated study)
- Vascular/cardiac damage due to investigation/operation:- Cardiac protection (depends on data from above study)
- Shock response after trauma:- Hypovolemic Shock ongoing preclinical research projects with US Army and US Air Force

Brand New IP:

- New Pharming patents filed in 2018 covering the new indications
- Patents cover all forms of rhC1INH

Potential addressable future markets






Expansion of pipeline to multiple products and markets

	Lead Optimization	Preclinical	Phase I	Phase II	Phase III	Approval & Commercialization	
RUCONEST®	Acute Hereditary Angioedema (HAE)						
RUCONEST	HAE Proph	ıylaxis (IV)					
® RUCONEST®	HAE Proph	iylaxis (SC ai	nd ID)				HAE-related
RUCONEST®	HAE Acute	(IM)					
RUCONEST®	Pre-Eclam	osia					
RUCONEST®	CIN and ca	rdiac protec	ction				
RUCONEST®	Delayed G	raft Functio	n				
RUCONEST®	Hemorrha	gic Shock					└─ Non-HAE-related
α-Glucosidase	Pompe		1				
α-Galactosidase	Fabry's		_				

Pompe diseases





- Progressive decrease in muscle strength starting with the legs and moving to smaller muscles in the trunk and arms, such as the diaphragm and other muscles required for breathing
- Cardiac failure and respiratory failure are the most common causes of death

Pompe diseases

α-glucosidase

Market potential for Pharming is over \$1 billion per year in each indication

- Attractive market:
 - All current products have severe shortcomings and boxed warnings, but together sell for over \$1 billion
 - Second generation products have their own shortcomings
 - Many patients are not on therapy because of antibody formation or adverse reactions
 - rhC1INH RUCONEST (equally highly-glycosylated) from our transgenic (rabbit) platform does not generate relevant antibody responses
 - A small 36-week clinical trial in infants with previous transgenic (rabbit-derived) rhaGLU showed good efficacy and did not report any safety concerns (2001)*





α-glucosidase

De novo proprietary constructs for our rabbit platform for rhaGLU have been developed and a new recombinant rhaGLU is being produced for initial clinical trial supplies

- New version is closer to natural human GAA than previous Pharming version, and also believed to be much closer than any other tested recombinant version to date
- α-glucosidase for Pompe disease now finalising last parts of manufacturing file and upscaling production to produce clinical trial material
- IND expected to begin 1H2019
- α-galactosidase for Fabry in mid preclinical development; expected to reach IND filing stage in 2020

Pompe diseases





Three horizons of growth





- Low volume IV
- Subcutaneous
- Intramuscular
- Painless intradermal
- Prophylaxis for HAE



Meeting other unmet medical needs with the same product

- Pre-eclampsia
- Others such as Contrast-induced Nephropathy, Cardiac Protection, Delayed Graft Function and Hypovolemic Shock

Meeting other unmet medical needs with another products

- α-glucosidase (Pompe)
- α-galactosidase (Fabry)
- Others




Add more RUCONEST[®] sales

Add more products to sell

Potential for significant newsflow over the coming years



Assumed solely for purpose of diagram: positive results of studies



Continued growth in sales of RUCONEST[®] driven by the US and EU operations

• Continuation of positive trend in operating results

12 Month Outlook


- Continuation of positive Net Earnings during the year
- Continued investment in the expansion of production of RUCONEST
- Research and (Clinical) Development investments:
 - RUCONEST[®] in HAE (SC/ID/IM) with low volume vial trials
 - Clinical trials for additional indications for RUCONEST®
 - New pipeline: Clinical development Pompe disease early 2019
- Increasing marketing activity, such as opening new countries for RUCONEST[®]
- Continue to support all our marketing partners to maximize the sales and distribution potential of RUCONEST[®] for patients in all territories

Increasing sales and continued positive results



Q&A with Leon Melens





Questions?



Sign up for our press releases, or ask further questions at info@pharming.com

www.pharming.com


Tickers: ENXTAM: PHARM Bloomberg: PHAR.AS





New Activities with rhC1INH: Pre-eclampsia






- Pre-eclampsia (PE) is a disorder of pregnancy characterized by the onset of high blood pressure and often a significant amount of protein in the urine.
- When it arises, the condition begins after 20 weeks of pregnancy. In severe disease there may be red blood cell breakdown, a low blood platelet count, impaired liver function, kidney dysfunction, swelling, shortness of breath due to fluid in the lungs, or visual disturbances.
- Pre-eclampsia increases the risk of poor outcomes for both the mother and the baby. If left untreated, it may result in seizures at which point it is known as eclampsia.

<u>A brief overview of Preeclampsia</u> <u>J Clin Med Res</u>. 2014 Feb; 6(1): 1–7. 2013 Dec 13. doi: <u>10.4021/jocmr1682w</u>

New Activities with rhC1INH: Contrast Induced Nephropathy (CIN)






 (CIN) is a form of kidney damage in which there has been recent exposure to medical imaging contrast material without another clear cause for the acute kidney injury.

Fabry's diseases





Symptoms: renal dysfunction,cardiac abnormalities,cerebrovascular manifestations,dermatological signs,ocular and auditory symptoms, neurological symptoms